Tovaxin
by admin on 09/09/09 at 10:38 am
Opexa Therapeutics, Inc. announced results from further analysis of the double-blind, placebo-controlled, 52-week Phase IIb TERMS clinical study of 150 patients with Relapsing Remitting MS (RRMS). This analysis evaluated patients with an annualized relapse rate of one or greater at study entry (ARR≥1). More than 83% of the Tovaxin-treated group (n=85) remained relapse free at one year and the annualized relapse rate after treatment decreased to 0.20, a 42% reduction compared to placebo.
73 percent of Tovaxin-treated patients showed stabilization or improvement in MS disability, including 16.5 percent with a sustained improvement of at least one full point on a standard disability scale.
Tovaxin possesses a unique dual mechanism of action that combats the demyelination of the nerve fibers in the central nervous system, the underlying cause of MS. Clinical results have demonstrated that Tovaxin produces the following therapeutic effects:
- Anti-idiotypic effect – The vaccine induces an immune response that depletes the circulating pathogenic MRTCs that attack the myelin sheath of nerve fibers and cause the symptoms of MS.
- Anti-ergotypic effect – Tovaxin also works to rebalance a patient’s overall immune system by causing a shift from pathogenic inflammatory T-cells to anti-inflammatory T-cells.
Leave a Comment